度伐利尤单抗致免疫相关性神经系统不良反应文献分析

Literature analysis of immune-related neurological adverse reactions induced by durvalumab

目的分析度伐利尤单抗所致免疫相关性神经系统不良反应的特点,为临床用药提供参考。方法以“度伐利尤单抗”、“安全性”、“不良反应”、“神经系统”、“Durvalumab”、“ADR”、“adverse drug reaction”、“adverse event”、“nervous system toxicities”、“neurological irAEs”为检索词,检索中国知网、万方、维普及PubMed、Web of Science数据库公开发表的使用度伐利尤单抗致神经系统不良反应的相关文献报道并进行分析。检索时间为建库至2022年9月30日。结果共纳入文献9篇,涉及度伐利尤单抗所致不良反应患者9例,患者年龄66~82岁。神经系统不良反应多发生在用药2~5周期内(55.56%)。常见的临床症状为肢体或全身无力(77.78%)。9例患者均停药,使用激素、免疫抑制剂、血浆置换等治疗。6例恢复或好转,1例未好转,2例死亡。结论临床医师应加强对度伐利尤单抗神经系统不良反应的监测,采取适当措施预防或治疗,避免严重不良反应的发生。

Objective To analyze the characteristics of neurological adverse drug reactions(ADRs)induced by durvalumab,so as to provide references for drug use in clinic.Methods Database of CNKI,Wanfang,VIP,PubMed and Web of Science were searched for literature reports on neurological adverse reactions induced by durvalumab with the key words of“durvalumab,ADR,adverse drug reaction,adverse event,nervous system toxicities,neurological irAEs”,and further analysis were performed.The retrieval time was from the time of establishment of database to September 30,2022.Results A total of 9 articles were included,involving 9 patients.The range of age was 66~82 years old.Neurological ADRs mostly occurred within 2~5 cycles of durvalumab(55.56%).The common clinical manifestations were weakness of limbs or the whole body(77.78%).All the 9 patients stopped taking the drug and received steroid treatment,immunosuppressant,plasmapheresis and so on.Six cases were improved or recovered,1 case was not improved,and 2 cases died.Conclusion Clinicians should strengthen the monitoring of neurological ADRs induced by durvalumab,and take appropriate preventive or therapeutic measures in order to avoid the occurrence of severe ADRs.